Another Major International European Airport Selects Implant Sciences' QS-B220

May 19, 2015, 09:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., May 19, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 20 of its QS-B220 desktop explosives trace detectors into Belgium for aviation security. Shipment of these units is already underway and is expected to be completed, per customer request, over the next several months.

"Implant Sciences has put an immense amount of effort into its manufacturing processes and capabilities. We believe that our ability to date to deliver products when a customer needs it most has helped us to secure additional wins in Europe, where EU regulations are driving strict airport procurement and implementation deadlines," stated Dr. Darryl Jones, Vice President of Global Sales and Marketing. "We believe that success will breed success as we hope to continue to capitalize on the significant opportunities in the region with our best-in-class trace detectors."

"Implant Sciences' established credibility, due to our superior performance in both lab and airport operational testing, has given us significant momentum throughout the ECAC procurements. We believe we are propelled forward even more so due to word of mouth, as one EU country is often influenced by a respected neighbor's buying decision," added Richard Nelson, Implant Sciences' General Manager of EMEA. "These frank discussions between security professionals about false alarm rates and operational readiness of the ETD and their impact on the bottom line of the airport have, we believe, helped Implant Sciences further penetrate the EU aviation market."

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for "Best Explosives Detection Solution" two years in a row (2013 and 2014).  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Implant Sciences Corporation 
Company Contact: 
Robert Liscouski
978-752-1700 x 116  

SOURCE Implant Sciences Corporation